Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | NNMT | P40261 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16753369 | 0.86 | GRIN2B (0.43) | GRIN2BBCL2HDAC1NAMPTGSK3B | |
| SCHEMBL19580238 | 0.85 | PRMT1 (0.49) | GRIN2BBCL2HDAC1NAMPTGSK3B | |
| SCHEMBL29651977 | 0.83 | HCAR3 (0.57) | GRIN2BBCL2HDAC1HCAR3 | |
| SCHEMBL28658285 | 0.83 | GRIN2B (0.48) | GRIN2BBCL2HDAC1NAMPTGSK3B | |
| SCHEMBL2877186 | 0.83 | HCAR3 (0.57) | GRIN2BBCL2HDAC1HCAR3 | |
| SCHEMBL31727242 | 0.83 | GRIN2B (0.48) | GRIN2BBCL2HDAC1NAMPTGSK3B | |
| SCHEMBL7936803 | 0.82 | HCAR3 (0.55) | GRIN2BBCL2HDAC1HCAR3 | |
| SCHEMBL5734042 | 0.82 | NNMT (0.58) | GRIN2BBCL2HDAC1NAMPTGSK3B | |
| SCHEMBL2772417 | 0.82 | MAPK1 (0.51) | GRIN2BBCL2HDAC1NAMPTGSK3B | |
| Acetic Acid SCHEMBL16753506 | 0.82 | GRIN2B (0.48) | GRIN2BBCL2HDAC1NAMPTGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-21 | — | — | US | disclosed |
| EP-3290413-B9 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3290413-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2019-11-13 | — | — | EP | disclosed |
| EP-3290413-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2018-03-07 | — | — | EP | disclosed |
| EP-2794597-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-20170305917-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-10-26 | — | — | US | disclosed |
| US-9732085-B2 | Pyridinone and pyrimidinone derivatives as factor Xia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20150152112-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152112-A1 | COMPOUNDS | F11, F12, F10 | GRIN2B 4551/4885BCL2 2818/4885HDAC1 559/4885 |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | GRIN2B 165/4885BCL2 1864/4885HDAC1 1048/4885 |
| US-20170305917-A1 | COMPOUNDS | F11, F12, F10 | GRIN2B 4551/4885BCL2 2818/4885HDAC1 559/4885 |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | F11, TFPI, F10 | GRIN2B 3991/4885BCL2 4543/4885HDAC1 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.